Inside a Big Pharma cancer drug approval with roots in a small Bay Area biotech

Before CAR-T therapies became one of the hottest areas of cancer drug development, Kristen Hege and her team looked at cell therapies to tackle HIV and solid tumors. More than 20 years later, Hege, now with drug giant Bristol-Myers Squibb Co., is diving into solid tumors again.